linkedin

Press Releases

Samsung BIO Insight

Exploring Samsung Biologics’ CDO capabilities | Bispecific antibodies

SamsungBIologics_S-DUAL_Newsroom_Thumbnail.jpg
 

Driven by advances in biotechnology, biopharmaceuticals are among the most sophisticated achievements of modern science and have become central to the industry. Antibody therapies, making up the largest share, have dramatically evolved since the approval of the first monoclonal antibody by the U.S. Food and Drug Administration in 1986. 

 

The efficacy and safety of bispecific antibodies, combined with their ability to address previously untreatable conditions and multifaceted diseases, illustrates how they represent a key component of the next-generation of antibody therapy.

 

According to the research and consulting firm Roots Analysis, the global bispecific antibody market is expected to grow at an annual rate of 34% to top $9 billion by 2030. The market is considered a blue ocean, with only two bispecific antibodies approved by both the FDA and European Medicine Agency for the treatment of cancer patients.

 

 

 

Attractive treatment modality 


Bispecific antibodies are capable of targeting two distinct antigens simultaneously, improving treatment potential compared to the conventional monoclonal antibodies that only target one type of antigen. 

 

Many complex diseases are driven by a variety of factors, which can circumvent the impact of a drug. Bispecific antibodies can improve the specificity and effectiveness, such as in the case of cancer immunotherapy. One arm binds to an antigen on a cancer cell, while the other binds to T-cells, bringing both cell types together to activate T-cells to eliminate the cancer cells.

 

 

SamsungBIologics_S-DUAL_1.jpg
 

However, there have been challenges in development of bispecific antibodies, especially regarding immunogenicity and chain mispairing, while issues in respect to the quality and stability have hampered their wider clinical application.

 

 

 

S-DUALTM boasts safety and optimal manufacturability


Samsung Biologics launched a new proprietary development technology platform, S-DUAL™ in September, boosting its strength in the CDO service. Having a unique asymmetric design, S-DUAL™ has high purity, yield and productivity.

 

SamsungBIologics_S-DUAL_2.jpg 

In the production of bispecific antibodies, only one of eight possible combinations is bispecific – requiring advanced technology to differentiate it. With a unique asymmetric design, S-DUAL™ can effectively separate and analyze the bispecific antibody as impurities from the improper pairings form different sizes.

 

 

SamsungBIologics_S-DUAL_3.jpg
 

It also applies ‘knob-in-hole’ technique to avoid mispairing between two heavy chains and light chains. This strategy provides high yield and maximum purity of 99%.

 

SamsungBIologics_S-DUAL_4.jpg
 

S-DUAL™ also has low immunogenicity due to human immunoglobulin gamma (lgG)-like structure. Samsung Biologics can design tailored antibody structures depending on clients’ needs. 

 

 

 

Biopharma’s new drug development partner


As Samsung Biologics provides end-to-end services, from contract development to contract manufacturing, it has a competitive edge in new drug development, where speed is crucial. Samsung Biologics has received over 160 regulatory approvals as of October 2022. 

 

The company has also strengthened its foothold as a new drug development partner by establishing a one-stop service from cell line development to commercial manufacturing, and opened an CDO R&D Center in San Francisco to provide services in close proximity to clients.

 

SamsungBIologics_S-DUAL_5.jpg
 

To meet fast-changing industry trends, Samsung also launched DEVELOPICKa developability assessment platform that screens molecules at an early stage to identify candidates with the best potential for advancement to Investigational New Drug, alongside the S-DUAL™. Samsung Biologics will continue to invest and take action to lead in the next-generation of biopharmaceuticals.

 

 

 

Related Content


Whitepapers Fundamental Considerations for Bispecific Antibody-based Cell Line Development

Samsung BIO Insight BioProcess International 2022 | Samsung Biologics unveils new development platforms to offer differentiated services


SamsungBIologics_S-DUAL_Newsroom_Thumbnail.jpg
 

Driven by advances in biotechnology, biopharmaceuticals are among the most sophisticated achievements of modern science and have become central to the industry. Antibody therapies, making up the largest share, have dramatically evolved since the approval of the first monoclonal antibody by the U.S. Food and Drug Administration in 1986. 

 

The efficacy and safety of bispecific antibodies, combined with their ability to address previously untreatable conditions and multifaceted diseases, illustrates how they represent a key component of the next-generation of antibody therapy.

 

According to the research and consulting firm Roots Analysis, the global bispecific antibody market is expected to grow at an annual rate of 34% to top $9 billion by 2030. The market is considered a blue ocean, with only two bispecific antibodies approved by both the FDA and European Medicine Agency for the treatment of cancer patients.

 

 

 

Attractive treatment modality 


Bispecific antibodies are capable of targeting two distinct antigens simultaneously, improving treatment potential compared to the conventional monoclonal antibodies that only target one type of antigen. 

 

Many complex diseases are driven by a variety of factors, which can circumvent the impact of a drug. Bispecific antibodies can improve the specificity and effectiveness, such as in the case of cancer immunotherapy. One arm binds to an antigen on a cancer cell, while the other binds to T-cells, bringing both cell types together to activate T-cells to eliminate the cancer cells.

 

 

SamsungBIologics_S-DUAL_1.jpg
 

However, there have been challenges in development of bispecific antibodies, especially regarding immunogenicity and chain mispairing, while issues in respect to the quality and stability have hampered their wider clinical application.

 

 

 

S-DUALTM boasts safety and optimal manufacturability


Samsung Biologics launched a new proprietary development technology platform, S-DUAL™ in September, boosting its strength in the CDO service. Having a unique asymmetric design, S-DUAL™ has high purity, yield and productivity.

 

SamsungBIologics_S-DUAL_2.jpg 

In the production of bispecific antibodies, only one of eight possible combinations is bispecific – requiring advanced technology to differentiate it. With a unique asymmetric design, S-DUAL™ can effectively separate and analyze the bispecific antibody as impurities from the improper pairings form different sizes.

 

 

SamsungBIologics_S-DUAL_3.jpg
 

It also applies ‘knob-in-hole’ technique to avoid mispairing between two heavy chains and light chains. This strategy provides high yield and maximum purity of 99%.

 

SamsungBIologics_S-DUAL_4.jpg
 

S-DUAL™ also has low immunogenicity due to human immunoglobulin gamma (lgG)-like structure. Samsung Biologics can design tailored antibody structures depending on clients’ needs. 

 

 

 

Biopharma’s new drug development partner


As Samsung Biologics provides end-to-end services, from contract development to contract manufacturing, it has a competitive edge in new drug development, where speed is crucial. Samsung Biologics has received over 160 regulatory approvals as of October 2022. 

 

The company has also strengthened its foothold as a new drug development partner by establishing a one-stop service from cell line development to commercial manufacturing, and opened an CDO R&D Center in San Francisco to provide services in close proximity to clients.

 

SamsungBIologics_S-DUAL_5.jpg
 

To meet fast-changing industry trends, Samsung also launched DEVELOPICKa developability assessment platform that screens molecules at an early stage to identify candidates with the best potential for advancement to Investigational New Drug, alongside the S-DUAL™. Samsung Biologics will continue to invest and take action to lead in the next-generation of biopharmaceuticals.

 

 

 

Related Content


Whitepapers Fundamental Considerations for Bispecific Antibody-based Cell Line Development

Samsung BIO Insight BioProcess International 2022 | Samsung Biologics unveils new development platforms to offer differentiated services


SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION